Native Cardio, Inc.
Minimally invasive medical devices and pharmaceuticals for cardiac disease treatment
- Sector
- Medtech
- Headquarters
- NAPLES, FL
- Founded
- 2018
- Latest Form D
- $150K, Mar 2025
- Total capital
- $2.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $2.2M
- 3 Form D · last Mar 2025
- 20 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 4 pending · first 2019
- Rank in peer group#425 of 1112
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$150K
- Private capital raisedForm D · SEC · 2nd filing$70K
- Private capital raisedForm D · SEC · 1st filing$2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1112 peers
Line = medianMedtech · Device
- Granted patents#425 · top 38%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Young D. KimResearcherDirectorLinked by 2 patents
- Christine Mikail CvijicDirectorNamed in SEC Form D filings
- Gary P. DixonExecutive OfficerNamed in SEC Form D filings
- Joseph V. PergolizziExecutive Officer, DirectorNamed in SEC Form D filings
- Joseph V. Pergolizzi, Jr.Executive Officer, Director, PromoterNamed in SEC Form D filings
- Myles P. Dempsey, Sr.DirectorNamed in SEC Form D filings
Show all 7 people
- Pedro Mikail GranadilloDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 6- PendingDefibrillator Interface Device For Atrial Cardioversion TherapyUSPTOApplication 18030629
- PendingDevice And Methods For Targeted Tissue Drug DeliveryUSPTOApplication 17556176
- GrantedDevice And Methods For Targeted Tissue Drug DeliveryUSPTOUS 11,224,718
Show all 6 patent records
- Defibrillator Interface Device For Atrial Cardioversion TherapyNov 23, 2023 · Application 18030629Pending
- Device And Methods For Targeted Tissue Drug DeliveryJun 2, 2022 · Application 17556176Pending
- Device And Methods For Targeted Tissue Drug DeliveryJan 18, 2022 · US 11,224,718Granted
- Device And Methods For Targeted Tissue Drug DeliveryOct 29, 2019 · US 10,456,553Granted
- Defibrillator Interface Device For Atrial Cardioversion TherapyApplication PCTUS2021054140Pending
- Defibrillator Interface Device For Atrial Cardioversion TherapyApplication 63089287Pending
Related companies, and why
- PASCAL MEDICAL CORPORATIONSimilar federal contract value in Medtech · null in contracts
- COSMOSID, INC.Similar federal contract value in Medtech · null in contracts
- CRYOLIFE INCSimilar federal contract value in Medtech · null in contracts
- Valar Labs, Inc.Similar federal contract value in Medtech · null in contracts
- PELVA HEALTH CORPORATIONSimilar federal contract value in Medtech · null in contracts
- EternaTear, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .